Galectin Therapeutics Inc. · NASDAQ:GALT

Galectin Therapeutics — PRO Pharmaceuticals — Investor Presentation (November 2006)

9 slides from Galectin Therapeutics's investor presentation, Nov 2, 2006

  1. Slide 1: Pro-Pharmaceuticals, Inc. - Advancing Drugs Through Glycoscience

    Exhibit 99.1 pro Q@rusnmaceuricacs, INC. ADVANCING DRUGS THROUGH GLYCOSCIENCE® aa é aA

  2. Slide 2: Key Investment Points

    P R O P H A R M A C E U T I C A L S , I N C. A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E ® Amex: P R W 4 Key Investment Points • Clinical stage pharmaceutical company – Completed Phase I/II cancer trials w/ DAVANAT – Stabilized 35% of end stage patients: 2-13 months – Two ongoi

  3. Slide 3: Clinical Trial Program

    5 Clinical Trial Program – Completed Phase I/II cancer trials w/ DAVANAT – Stabilized 35% of end stage patients: 2-13 months – Two ongoing Phase II front line trials * *

  4. Slide 4: Phase I Patient Summary: Stabilized 70% at Highest Dose Level

    P R O P H A R M A C E U T I C A L S , I N C. A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E ® Amex: P R W 8 SD Stable Disease PD Progressive Disease NM Non-Measurable Disease Cycles Completed Dose, cycle 2 /m2 1+2 1001 PD 1002 SD 2001 Hepatocellular PD 2002 Hepatocellular SD 3001

  5. Slide 5: Increases the Half Life of 5-FU, Fold with No Increase in Toxicity

    12 Increases the Half Life of 5-FU, 8 Fold with No Increase in Toxicity * *

  6. Slide 6: Increases Half Life of 5-FU in Patients, 8 times

    P R O P H A R M A C E U T I C A L S , I N C. A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E ® Amex: P R W Increases Half Life of 5-FU in Patients, 8 times 5-FU / DAVANAT – Day 4 5-FU / DAVANAT – Day 1 5-FU – Historical

  7. Slide 7: 5-FU in the Presence of DAVANAT Does Not Change Key Toxicity Markers

    P R O P H A R M A C E U T I C A L S , I N C. A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E ® Amex: P R W 5-FU in the presence of Does Not Change Key Toxicity Markers AUC Hematocrit Hemoglobin Red blood cells White blood cells Platelets

  8. Slide 8: The DAVANAT/5-FU Model Can Be Applied to Other Chemotherapy Agents

    The /5-FU Model Can Be Applied To Increasing Efficacy/ Decreasing Toxicity of Other Chemotherapy Agents

  9. Slide 9: Combination with another chemotherapy agent: tumor growth over time

    P R O P H A R M A C E U T I C A L S , I N C. A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E ® Amex: P R W 16 with another Chemotherapy Agent 1000 10000 Time post implanatation (Days) Control IR40/DAV6 IR40/DAV30 IR40/DAV120

PRO Pharmaceuticals — Investor Presentation (November 2006) on 6ix